カテゴリー： MarketsandMarkets, 世界, 医療/バイオ

世界の止血剤市場（～2028年）：種類別（トロンビン、酸化再生セルロース、コンビネーション、ゼラチン、コラーゲン）、剤型別（マトリックス＆ゲル、シート＆パッド、スポンジ、パウダー）、用途別（整形外科、神経外科、心臓血管外科）、地域別

◆英語タイトル：Hemostats Market by Type (Thrombin, Oxidized Regenerated Cellulose, Combination, Gelatin, Collagen), Formulation (Matrix & Gel, Sheet & Pad, Sponge, Powder), Application (Orthopedic, Neurological, Cardiovascular Surgery), Region - Global Forecast to 2028
	◆商品コード：MD4093-23 ◆発行会社（リサーチ会社）：MarketsandMarkets ◆発行日：2023年10月17日 ◆ページ数：223 ◆レポート形式：英語 / PDF ◆納品方法：Eメール（受注後24時間以内） ◆調査対象地域：グローバル ◆産業分野：医療機器

◆販売価格オプション（消費税別）

Single User（1名様閲覧）	USD4,950 ⇒換算￥752,400	見積依頼/購入/質問フォーム
Multi User (Five User)	USD6,650 ⇒換算￥1,010,800	見積依頼/購入/質問フォーム
Corporate License (全社内共有可)	USD8,150 ⇒換算￥1,238,800	見積依頼/購入/質問フォーム

★MarketsandMarketsに受託調査の見積を依頼する

※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

"止血剤市場は2023年に推定27億米ドルと評価され、予測期間中のCAGRは6.7%で2028年までに37億米ドルに達すると予測" 老年人口は、外科手術の需要が高まっている人口統計学的なセグメントを表しており、したがって、現代の医療における止血剤の重要な必要性を強調しています。高齢化が進むと、さまざまな病状や慢性疾患にかかりやすくなり、生活の質を維持・向上させるために外科的治療が必要になることが多くなります。このような外科的介入は、整形外科的な関節置換術、複雑な心臓手術、複雑な消化管手術など、広い範囲に及びます。組織の弾力性の低下や出血に対する脆弱性の高まりなど、加齢に伴う生理的変化を考慮すると、止血剤を正確かつ効率的に使用することは、高齢患者の外科治療において最も重要な意味を持ちます。世界の高齢者人口が着実に増加するにつれて、止血剤の需要は比例して増加すると予想され、外科治療を受ける高齢者の微妙な医療ニーズに対応する上で不可欠な役割が強調されています。

"予測期間中、タイプ別止血剤市場で最も高い成長率を占めたのはコンビネーション型止血剤"
止血剤市場は、タイプ別に酸化再生セルロース系止血剤、トロンビン系止血剤、コンビネーション止血剤、ゼラチン系止血剤、コラーゲン系止血剤、その他止血剤に二分されます。止血剤のうち、コンビネーション止血剤が大きく伸長しています。コンビネーション止血剤は単剤止血剤よりも止血効果が高いことが多いです。これは、異なる種類の止血剤の長所を併せ持つためです。

"予測期間中の止血剤市場において、剤形別ではスポンジ止血剤が最も高い成長率を占め"
世界の止血剤市場は、マトリックス・ゲル止血剤、シート・パッド止血剤、スポンジ止血剤、粉末止血剤に二分されます。現在、止血剤市場の中で最も高い成長率を示しているのはスポンジ止血剤分野です。市場成長の主な要因は、スポンジ止血剤に関連するさまざまな利点により、エンドユーザーに受け入れられるようになったことです。

"アジア太平洋地域：最も急成長している地域の止血剤市場"
世界の止血剤市場は、北米、欧州、アジア太平洋地域、中南米、中東・アフリカに区分されます。予測期間中に最も高い成長が見込まれるのはアジア太平洋市場です。この地域の新興国はGDPの成長と可処分所得水準の大幅な上昇を目の当たりにしています。このため、より多くの人口が医療支出を増加させています。このほか、慢性疾患の罹患率・有病率の増加、外科手術の負担増、医療インフラの近代化、アジア太平洋諸国における最先端技術の浸透（特に農村部）なども、同地域の止血剤企業に大きな成長機会をもたらすと期待されています。また、疾病管理に対する意識を高めるための政府の取り組みや、インドや中国における病院・診療所の増加なども成長の要因となっています。アジア諸国の医療費支出も大幅に増加しています。医療費の増加は、医療提供者の購買力を高め、止血剤を含む先進的な医療・手術用品の採用を刺激します。

止血剤市場における主要参入企業のプロファイルの内訳
- 企業タイプ別：企業タイプ別：Tier 1 - 40%、Tier 2 - 30%、Tier 3 - 30%
- 役職別 Cレベル：27％、Dレベル：18％、その他：55%
- 地域別北米：51%、欧州：21%、アジア太平洋地域：18%、中南米：6%、中東・アフリカ：4%

同市場の主要プレーヤーは、Johnson & Johnson (US), Baxter International (US), Pfizer Inc. (US), B. Braun SE (Germany), Becton, Dickinson and Company (US), Teleflex Incorporated (US), Medtronic Plc (Ireland), Hemostasis, LLC (US), Stryker Corporation (US), Integra LifeSciences (US), Advanced Medical Solutions Group Plc (UK), Samyang Holdings Corporation (South Korea), Marine Polymer Technologies, Inc. (US), GELITA MEDICAL GmbH (Germany), Dilon Technologies, Inc. (US), Betatech Medical (Turkey), Meril Life Sciences Pvt. Ltd. (India), BioCer Entwicklungs-GmbH (Germany), Unilene (US), Katsan Medical Devices (Turkey), Tricol Biomedical (US), 3-D Matrix Medical Technology (Japan), Hemostat Medical GmbH (Germany), Medtrade Products Limited (UK), and Altaylar Medical (Turkey)などです。

調査範囲
この調査レポートは、止血剤市場をタイプ別（トロンビンベースの止血剤、酸化再生セルロースベースの止血剤、コンビネーション止血剤、ゼラチンベースの止血剤、コラーゲンベースの止血剤、その他の止血剤）、剤型別（整形外科、一般外科、神経外科、心臓血管外科、再建外科、用途（マトリックス・ゲル止血剤、シート・パッド止血剤、スポンジ止血剤、粉末止血剤）、地域（北米、欧州、アジア太平洋、中南米、中東・アフリカ）などで分類されています。本レポートでは、止血剤市場の成長に影響を与える促進要因、阻害要因、機会、課題などの主要要因に関する詳細情報を網羅しています。主要な業界プレイヤーを詳細に分析し、事業概要、ソリューション、主要戦略、買収、契約などに関する洞察を提供します。止血剤市場に関連する新製品・サービスの発表と最近の動向が載せられています。止血器具市場のエコシステムにおける今後の新興企業の競争分析もカバーしています。

本レポートを購入する理由
本レポートは、止血剤市場全体およびサブセグメントにおける収益数の最も近い概算に関する情報を提供することで、同市場の市場リーダー／新規参入者に役立ちます。本レポートは、利害関係者が競争状況を理解し、自社のビジネスをより良く位置づけ、適切な市場参入戦略を計画するためのより多くの洞察を得るのに役立ちます。また、本レポートは、関係者が市場の鼓動を理解するのに役立ち、主要な市場促進要因、阻害要因、機会、および課題に関する情報を提供します。

本レポートは、以下のポイントに関する洞察を提供します：
- 止血剤市場の成長に影響を与える主な促進要因（手術件数の増加、研究開発への注目の高まり、手術中の患者の効果的な失血管理への注目の高まり）、阻害要因（止血剤に関連する副作用やアレルギー反応）、機会（新興国での成長機会、病院数の増加）、課題（厳しい規制の枠組み、止血剤を効果的に使用できる熟練者の不足、止血剤の高コスト）の分析を行っています。
- 製品開発／イノベーション：止血剤市場における今後の技術、研究開発活動、新製品発売に関する詳細な洞察を提供します。
- 市場開発：有利な市場に関する包括的な情報 - 当レポートでは、さまざまな地域の止血剤市場を分析しています。
- 市場の多様化：止血剤市場における新製品・サービス、未開拓の地域、最近の開発、投資に関する詳細な情報を提供します。
- 競合評価：Johnson & Johnson (US), Baxter International (US), Pfizer Inc. (US), B. Braun SE (Germany), and Becton, Dickinson and Company (US)など、止血剤市場戦略における主要企業の市場シェア、成長戦略、サービス内容を詳細に評価します。

1 イントロダクション
2 調査方法
3 エグゼクティブサマリー
4 プレミアムインサイト
5 市場概要
6 止血剤の世界市場：タイプ別
7 止血剤の世界市場：製剤別
8 止血剤の世界市場：用途別
9 止血剤の世界市場：地域別
10 競争状況
11 企業情報
12 付録

❖ レポートの目次 ❖

1 INTRODUCTION 21
1.1 STUDY OBJECTIVES 21
1.2 MARKET DEFINITION 21
1.2.1 INCLUSIONS & EXCLUSIONS 22
1.3 STUDY SCOPE 22
1.3.1 HEMOSTATS MARKET 22
1.3.2 GEOGRAPHIC SCOPE 23
1.3.3 YEARS CONSIDERED 23
1.4 CURRENCY 23
1.5 LIMITATIONS 24
1.6 STAKEHOLDERS 24
1.7 SUMMARY OF CHANGES 24
2 RESEARCH METHODOLOGY 26
2.1 RESEARCH DATA 26
2.2 RESEARCH APPROACH 26
FIGURE 1 HEMOSTATS MARKET: RESEARCH DESIGN METHODOLOGY 26
2.2.1 SECONDARY DATA 27
2.2.1.1 Key data from secondary sources 27
2.2.2 PRIMARY DATA 28
2.2.2.1 Primary sources 29
2.2.2.2 Key data from primary sources 29
2.2.2.3 Key industry insights 30
2.2.2.4 Breakdown of primary interviews 30
FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS 30
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 31
2.3 MARKET SIZE ESTIMATION 31
2.3.1 BOTTOM-UP APPROACH 32
2.3.1.1 Approach 1: Company revenue estimation approach 32
FIGURE 4 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH 32
2.3.1.2 Approach 2: Presentations of companies and primary interviews 32
2.3.1.3 Growth forecast 33
2.3.1.4 CAGR projections 33
FIGURE 5 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 33
2.3.2 TOP-DOWN APPROACH 33
FIGURE 6 HEMOSTATS MARKET: TOP-DOWN APPROACH 34
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION 35
FIGURE 7 DATA TRIANGULATION METHODOLOGY 35
2.5 MARKET SHARE ANALYSIS 36
2.6 STUDY ASSUMPTIONS 36
2.7 GROWTH RATE ASSUMPTIONS 36
2.8 RISK ASSESSMENT 37
2.8.1 RISK ASSESSMENT: HEMOSTATS MARKET 37
2.9 RECESSION IMPACT 37
3 EXECUTIVE SUMMARY 39
FIGURE 8 HEMOSTATS MARKET, BY TYPE, 2023 VS. 2028 (USD MILLION) 39
FIGURE 9 HEMOSTATS MARKET, BY FORMULATION, 2023 VS. 2028 (USD MILLION) 40
FIGURE 10 HEMOSTATS MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION) 40
FIGURE 11 HEMOSTATS MARKET, BY REGION, 2023 VS. 2028 (USD MILLION) 41
4 PREMIUM INSIGHTS 42
4.1 HEMOSTATS MARKET OVERVIEW 42
FIGURE 12 GROWING NEED TO MANAGE BLOOD LOSS IN PATIENTS DURING SURGICAL PROCEDURES TO DRIVE MARKET GROWTH 42
4.2 HEMOSTATS MARKET SHARE, BY TYPE, 2023 VS. 2028 42
FIGURE 13 OXIDIZED REGENERATED CELLULOSE-BASED HEMOSTATS TO CONTINUE TO DOMINATE MARKET IN 2028 42
4.3 HEMOSTATS MARKET SHARE, BY FORMULATION, 2023 VS. 2028 43
FIGURE 14 MATRIX & GEL HEMOSTATS SEGMENT TO ACCOUNT FOR LARGEST MARKET SHARE DURING FORECAST PERIOD 43
4.4 HEMOSTATS MARKET SHARE, BY APPLICATION, 2023 VS. 2028 43
FIGURE 15 ORTHOPEDIC SURGERY SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD 43
4.5 HEMOSTATS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 44
FIGURE 16 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE IN HEMOSTATS MARKET DURING FORECAST PERIOD 44
5 MARKET OVERVIEW 45
5.1 INTRODUCTION 45
5.2 MARKET DYNAMICS 45
FIGURE 17 HEMOSTATS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 45
5.2.1 DRIVERS 46
5.2.1.1 Growing volume of surgical procedures performed 46
TABLE 1 TOTAL NUMBER OF KNEE REPLACEMENTS, 2021 47
TABLE 2 TOTAL NUMBER OF CORONARY ARTERY BYPASS GRAFT PROCEDURES, 2021 48
5.2.1.2 Rising focus on R&D 48
5.2.1.3 Rising focus on effective blood loss management in patients during surgeries 49
5.2.2 RESTRAINTS 49
5.2.2.1 Side effects and allergic reactions associated with hemostats 49
5.2.3 OPPORTUNITIES 50
5.2.3.1 Growth opportunities in emerging economies 50
TABLE 3 COST OF SURGICAL PROCEDURES: US VS. INDIA (USD) 50
5.2.3.2 Growing number of hospitals 51
5.2.4 CHALLENGES 51
5.2.4.1 Stringent regulatory framework 51
5.2.4.2 Dearth of skilled personnel for effective use of hemostats 52
5.2.4.3 High cost of hemostats 52
5.3 PRICING ANALYSIS 52
5.3.1 INDICATIVE PRICING MODEL ANALYSIS OF MARKET PLAYERS 52
TABLE 4 INDICATIVE PRICING FOR HEMOSTATS 52
5.3.2 AVERAGE SELLING PRICE OF HEMOSTATS, BY REGION 53
TABLE 5 AVERAGE SELLING PRICE OF HEMOSTATS 53
5.4 VALUE CHAIN ANALYSIS 53
FIGURE 18 VALUE CHAIN ANALYSIS OF HEMOSTATS MARKET: MAJOR VALUE ADDED DURING MANUFACTURING AND ASSEMBLY PHASES 54
5.5 SUPPLY CHAIN ANALYSIS 55
FIGURE 19 HEMOSTATS MARKET: SUPPLY CHAIN ANALYSIS 55
5.6 PATENT ANALYSIS 56
FIGURE 20 PATENT ANALYSIS FOR HEMOSTATS (JANUARY 2013–DECEMBER 2022) 56
5.6.1 LIST OF MAJOR PATENTS 57
5.7 TRADE ANALYSIS 57
5.7.1 TRADE ANALYSIS FOR HEMOSTATS 57
TABLE 6 IMPORT DATA FOR HEMOSTATS, BY COUNTRY, 2018–2022 (USD MILLION) 57
TABLE 7 EXPORT DATA FOR HEMOSTATS, BY COUNTRY, 2018–2022 (USD MILLION) 58
5.8 ECOSYSTEM ANALYSIS 58
FIGURE 21 HEMOSTATS MARKET: ECOSYSTEM ANALYSIS 58
5.8.1 HEMOSTATS MARKET: ROLE IN ECOSYSTEM 59
5.9 PORTER’S FIVE FORCES ANALYSIS 59
TABLE 8 HEMOSTATS MARKET: PORTER’S FIVE FORCES ANALYSIS 59
5.9.1 THREAT OF NEW ENTRANTS 60
5.9.2 THREAT OF SUBSTITUTES 60
5.9.3 BARGAINING POWER OF SUPPLIERS 60
5.9.4 BARGAINING POWER OF BUYERS 60
5.9.5 INTENSITY OF COMPETITIVE RIVALRY 61
5.10 REGULATORY LANDSCAPE 61
TABLE 9 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 61
TABLE 10 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 62
TABLE 11 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 62
TABLE 12 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 62
5.10.1 NORTH AMERICA 63
5.10.1.1 US 63
TABLE 13 CLASSIFICATION OF MEDICAL DEVICES BY US FDA 63
FIGURE 22 PREMARKET NOTIFICATION: 510(K) APPROVAL FOR MEDICAL DEVICES 64
5.10.1.2 Canada 64
FIGURE 23 APPROVAL PROCESS FOR CLASS III MEDICAL DEVICES IN CANADA 64
5.10.2 EUROPE 65
FIGURE 24 CE APPROVAL PROCESS IN EUROPE FOR HEMOSTATS 65
5.10.3 ASIA PACIFIC 65
5.10.3.1 Japan 65
TABLE 14 CLASSIFICATION OF MEDICAL DEVICES AND REVIEWING BODY IN JAPAN 66
5.10.3.2 China 66
TABLE 15 NMPA MEDICAL DEVICES CLASSIFICATION 66
5.10.3.3 India 67
5.11 TECHNOLOGY ANALYSIS 67
5.12 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 68
FIGURE 25 REVENUE SHIFT IN HEMOSTATS MARKET 68
6 HEMOSTATS MARKET, BY TYPE 69
6.1 INTRODUCTION 70
TABLE 16 HEMOSTATS MARKET, BY TYPE, 2018–2021 (USD MILLION) 70
TABLE 17 HEMOSTATS MARKET, BY TYPE, 2022–2028 (USD MILLION) 70
6.2 PRIMARY NOTES 71
6.2.1 KEY PRIMARY INSIGHTS 71
6.3 OXIDIZED REGENERATED CELLULOSE-BASED HEMOSTATS 71
6.3.1 GROWING AVAILABILITY OF ORC-BASED HEMOSTATIC AGENTS ACROSS UNTAPPED MARKETS TO DRIVE GROWTH 71
TABLE 18 MAJOR PRODUCTS IN OXIDIZED REGENERATED CELLULOSE-BASED HEMOSTATS MARKET 72
TABLE 19 OXIDIZED REGENERATED CELLULOSE-BASED HEMOSTATS MARKET, BY REGION, 2018–2021 (USD MILLION) 73
TABLE 20 OXIDIZED REGENERATED CELLULOSE-BASED HEMOSTATS MARKET, BY REGION, 2022–2028 (USD MILLION) 73
6.4 THROMBIN-BASED HEMOSTATS 73
6.4.1 DEVELOPMENTS IN RECOMBINANT THROMBIN PRODUCTS TO SUPPORT GROWTH 73
TABLE 21 MAJOR PRODUCTS IN THROMBIN-BASED HEMOSTATS MARKET 74
TABLE 22 THROMBIN-BASED HEMOSTATS MARKET, BY REGION, 2018–2021 (USD MILLION) 74
TABLE 23 THROMBIN-BASED HEMOSTATS MARKET, BY REGION, 2022–2028 (USD MILLION) 75
6.5 COMBINATION HEMOSTATS 75
6.5.1 ADVANCEMENTS IN COMBINATION MATERIALS TO PROPEL MARKET GROWTH 75
TABLE 24 MAJOR PRODUCTS IN COMBINATION HEMOSTATS MARKET 76
TABLE 25 COMBINATION HEMOSTATS MARKET, BY REGION, 2018–2021 (USD MILLION) 76
TABLE 26 COMBINATION HEMOSTATS MARKET, BY REGION, 2022–2028 (USD MILLION) 76
6.6 GELATIN-BASED HEMOSTATS 77
6.6.1 HIGH ELASTICITY OFFERED BY GELATIN-BASED HEMOSTATS TO BOOST DEMAND 77
TABLE 27 MAJOR PRODUCTS IN GELATIN-BASED HEMOSTATS MARKET 77
TABLE 28 GELATIN-BASED HEMOSTATS MARKET, BY REGION, 2018–2021 (USD MILLION) 77
TABLE 29 GELATIN-BASED HEMOSTATS MARKET, BY REGION, 2022–2028 (USD MILLION) 78
6.7 COLLAGEN-BASED HEMOSTATS 78
6.7.1 LOW COST AND REDUCED RISK OF DISEASE TRANSMISSION TO PROMOTE ADOPTION OF COLLAGEN-BASED HEMOSTATS 78
TABLE 30 MAJOR PRODUCTS IN COLLAGEN-BASED HEMOSTATS MARKET 79
TABLE 31 COLLAGEN-BASED HEMOSTATS MARKET, BY REGION, 2018–2021 (USD MILLION) 79
TABLE 32 COLLAGEN-BASED HEMOSTATS MARKET, BY REGION, 2022–2028 (USD MILLION) 79
6.8 OTHER HEMOSTATS 80
TABLE 33 OTHER HEMOSTATS MARKET, BY REGION, 2018–2021 (USD MILLION) 80
TABLE 34 OTHER HEMOSTATS MARKET, BY REGION, 2022–2028 (USD MILLION) 80
7 HEMOSTATS MARKET, BY FORMULATION 81
7.1 INTRODUCTION 82
TABLE 35 HEMOSTATS MARKET, BY FORMULATION, 2018–2021 (USD MILLION) 82
TABLE 36 HEMOSTATS MARKET, BY FORMULATION, 2022–2028 (USD MILLION) 82
7.2 MATRIX & GEL HEMOSTATS 83
7.2.1 ABILITY OF MATRIX & GEL HEMOSTATS TO ENHANCE PLATELET AGGREGATION TO BOOST MARKET 83
TABLE 37 MATRIX & GEL HEMOSTATS MARKET, BY REGION, 2018–2021 (USD MILLION) 83
TABLE 38 MATRIX & GEL HEMOSTATS MARKET, BY REGION, 2022–2028 (USD MILLION) 83
7.3 SHEET & PAD HEMOSTATS 84
7.3.1 ABILITY TO CUT SHEET & PAD HEMOSTATS INTO ANY SHAPE OR SIZE TO FUEL ADOPTION 84
TABLE 39 SHEET & PAD HEMOSTATS MARKET, BY REGION, 2018–2021 (USD MILLION) 84
TABLE 40 SHEET & PAD HEMOSTATS MARKET, BY REGION, 2022–2028 (USD MILLION) 84
7.4 SPONGE HEMOSTATS 85
7.4.1 GROWING ACCEPTANCE OF SPONGE HEMOSTATS TO FUEL UPTAKE 85
TABLE 41 SPONGE HEMOSTATS MARKET, BY REGION, 2018–2021 (USD MILLION) 85
TABLE 42 SPONGE HEMOSTATS MARKET, BY REGION, 2022–2028 (USD MILLION) 85
7.5 POWDER HEMOSTATS 86
7.5.1 ABILITY TO SPRAY POWDER FORMULATIONS DIRECTLY ON WOUNDS TO FUEL DEMAND 86
TABLE 43 POWDER HEMOSTATS MARKET, BY REGION, 2018–2021 (USD MILLION) 86
TABLE 44 POWDER HEMOSTATS MARKET, BY REGION, 2022–2028 (USD MILLION) 87
8 HEMOSTATS MARKET, BY APPLICATION 88
8.1 INTRODUCTION 89
TABLE 45 HEMOSTATS MARKET, BY APPLICATION, 2018–2021 (USD MILLION) 89
TABLE 46 HEMOSTATS MARKET, BY APPLICATION, 2022–2028 (USD MILLION) 89
8.2 PRIMARY NOTES 90
8.2.1 KEY PRIMARY INSIGHTS 90
8.3 ORTHOPEDIC SURGERY 90
8.3.1 INCREASING INCIDENCE OF SPORTS INJURIES TO SUPPORT MARKET GROWTH 90
TABLE 47 NUMBER OF KNEE & HIP REPLACEMENTS, 2021 91
TABLE 48 HEMOSTATS MARKET FOR ORTHOPEDIC SURGERY, BY REGION, 2018–2021 (USD MILLION) 91
TABLE 49 HEMOSTATS MARKET FOR ORTHOPEDIC SURGERY, BY REGION, 2022–2028 (USD MILLION) 92
8.4 GENERAL SURGERY 92
8.4.1 INCREASING NUMBER OF HERNIA REPAIR PROCEDURES TO DRIVE GROWTH 92
TABLE 50 TOTAL NUMBER OF INGUINAL HERNIA REPAIR PROCEDURES, 2021 93
TABLE 51 HEMOSTATS MARKET FOR GENERAL SURGERY, BY REGION, 2018–2021 (USD MILLION) 93
TABLE 52 HEMOSTATS MARKET FOR GENERAL SURGERY, BY REGION, 2022–2028 (USD MILLION) 93
8.5 NEUROLOGICAL SURGERY 94
8.5.1 GROWING PREVALENCE OF NEUROLOGICAL DISORDERS TO DRIVE MARKET GROWTH 94
TABLE 53 HEMOSTATS MARKET FOR NEUROLOGICAL SURGERY, BY REGION, 2018–2021 (USD MILLION) 94
TABLE 54 HEMOSTATS MARKET FOR NEUROLOGICAL SURGERY, BY REGION, 2022–2028 (USD MILLION) 94
8.6 CARDIOVASCULAR SURGERY 95
8.6.1 RISING PREVALENCE OF CVD TO DRIVE ADOPTION OF HEMOSTATS 95
TABLE 55 HEMOSTATS MARKET FOR CARDIOVASCULAR SURGERY, BY REGION, 2018–2021 (USD MILLION) 95
TABLE 56 HEMOSTATS MARKET FOR CARDIOVASCULAR SURGERY, BY REGION, 2022–2028 (USD MILLION) 96
8.7 RECONSTRUCTIVE SURGERY 96
8.7.1 GROWING NUMBER OF COSMETIC SURGERIES TO SUPPORT MARKET GROWTH 96
TABLE 57 HEMOSTATS MARKET FOR RECONSTRUCTIVE SURGERY, BY REGION, 2018–2021 (USD MILLION) 97
TABLE 58 HEMOSTATS MARKET FOR RECONSTRUCTIVE SURGERY, BY REGION, 2022–2028 (USD MILLION) 97
8.8 GYNECOLOGICAL SURGERY 97
8.8.1 GROWING USE OF HEMOSTATS IN C-SECTION PROCEDURES TO CONTROL SURGICAL BLEEDING TO SUPPORT GROWTH 97
TABLE 59 HEMOSTATS MARKET FOR GYNECOLOGICAL SURGERY, BY REGION, 2018–2021 (USD MILLION) 98
TABLE 60 HEMOSTATS MARKET FOR GYNECOLOGICAL SURGERY, BY REGION, 2022–2028 (USD MILLION) 98
8.9 OTHER SURGICAL APPLICATIONS 99
TABLE 61 HEMOSTATS MARKET FOR OTHER SURGICAL APPLICATIONS, BY REGION, 2018–2021 (USD MILLION) 99
TABLE 62 HEMOSTATS MARKET FOR OTHER SURGICAL APPLICATIONS, BY REGION, 2022–2028 (USD MILLION) 100
9 HEMOSTATS MARKET, BY REGION 101
9.1 INTRODUCTION 102
TABLE 63 HEMOSTATS MARKET, BY REGION, 2018–2021 (USD MILLION) 102
TABLE 64 HEMOSTATS MARKET, BY REGION, 2022–2028 (USD MILLION) 102
9.2 NORTH AMERICA 103
FIGURE 26 NORTH AMERICA: HEMOSTATS MARKET SNAPSHOT 104
TABLE 65 NORTH AMERICA: HEMOSTATS MARKET, BY COUNTRY, 2018–2021 (USD MILLION) 104
TABLE 66 NORTH AMERICA: HEMOSTATS MARKET, BY COUNTRY, 2022–2028 (USD MILLION) 105
TABLE 67 NORTH AMERICA: HEMOSTATS MARKET, BY TYPE, 2018–2021 (USD MILLION) 105
TABLE 68 NORTH AMERICA: HEMOSTATS MARKET, BY TYPE, 2022–2028 (USD MILLION) 105
TABLE 69 NORTH AMERICA: HEMOSTATS MARKET, BY FORMULATION, 2018–2021 (USD MILLION) 106
TABLE 70 NORTH AMERICA: HEMOSTATS MARKET, BY FORMULATION, 2022–2028 (USD MILLION) 106
TABLE 71 NORTH AMERICA: HEMOSTATS MARKET, BY APPLICATION, 2018–2021 (USD MILLION) 106
TABLE 72 NORTH AMERICA: HEMOSTATS MARKET, BY APPLICATION, 2022–2028 (USD MILLION) 107
9.2.1 NORTH AMERICA: RECESSION IMPACT 107
9.2.2 US 107
9.2.2.1 Strong healthcare infrastructure to support uptake of hemostats 107
TABLE 73 US: HEMOSTATS MARKET, BY TYPE, 2018–2021 (USD MILLION) 108
TABLE 74 US: HEMOSTATS MARKET, BY TYPE, 2022–2028 (USD MILLION) 109
9.2.3 CANADA 109
9.2.3.1 Growing geriatric population and increasing volume of surgeries to drive demand for hemostats 109
TABLE 75 SURGICAL PROCEDURES PERFORMED IN CANADA, 2021 110
TABLE 76 CANADA: KEY MACROINDICATORS 110
TABLE 77 CANADA: HEMOSTATS MARKET, BY TYPE, 2018–2021 (USD MILLION) 110
TABLE 78 CANADA: HEMOSTATS MARKET, BY TYPE, 2022–2028 (USD MILLION) 111
9.3 EUROPE 111
TABLE 79 EUROPE: HEMOSTATS MARKET, BY COUNTRY, 2018–2021 (USD MILLION) 112
TABLE 80 EUROPE: HEMOSTATS MARKET, BY COUNTRY, 2022–2028 (USD MILLION) 112
TABLE 81 EUROPE: HEMOSTATS MARKET, BY TYPE, 2018–2021 (USD MILLION) 113
TABLE 82 EUROPE: HEMOSTATS MARKET, BY TYPE, 2022–2028 (USD MILLION) 113
TABLE 83 EUROPE: HEMOSTATS MARKET, BY FORMULATION, 2018–2021 (USD MILLION) 113
TABLE 84 EUROPE: HEMOSTATS MARKET, BY FORMULATION, 2022–2028 (USD MILLION) 114
TABLE 85 EUROPE: HEMOSTATS MARKET, BY APPLICATION, 2018–2021 (USD MILLION) 114
TABLE 86 EUROPE: HEMOSTATS MARKET, BY APPLICATION, 2022–2028 (USD MILLION) 114
9.3.1 EUROPE: RECESSION IMPACT 115
9.3.2 GERMANY 115
9.3.2.1 High healthcare expenditure in Germany to favor market growth 115
TABLE 87 SURGICAL PROCEDURES PERFORMED IN GERMANY, 2021 116
TABLE 88 GERMANY: KEY MACROINDICATORS 116
TABLE 89 GERMANY: HEMOSTATS MARKET, BY TYPE, 2018–2021 (USD MILLION) 116
TABLE 90 GERMANY: HEMOSTATS MARKET, BY TYPE, 2022–2028 (USD MILLION) 117
9.3.3 UK 117
9.3.3.1 Growing volume of hernia repair and cardiovascular surgeries to drive market growth 117
TABLE 91 SURGICAL PROCEDURES PERFORMED IN UK, 2021 118
TABLE 92 UK: KEY MACROINDICATORS 118
TABLE 93 UK: HEMOSTATS MARKET, BY TYPE, 2018–2021 (USD MILLION) 118
TABLE 94 UK: HEMOSTATS MARKET, BY TYPE, 2022–2028 (USD MILLION) 119
9.3.4 FRANCE 119
9.3.4.1 Presence of well-established healthcare system to propel market growth 119
TABLE 95 SURGICAL PROCEDURES PERFORMED IN FRANCE, 2021 120
TABLE 96 FRANCE: KEY MACROINDICATORS 120
TABLE 97 FRANCE: HEMOSTATS MARKET, BY TYPE, 2018–2021 (USD MILLION) 120
TABLE 98 FRANCE: HEMOSTATS MARKET, BY TYPE, 2022–2028 (USD MILLION) 121
9.3.5 ITALY 121
9.3.5.1 Increasing volume of surgeries to drive demand for hemostats 121
TABLE 99 SURGICAL PROCEDURES PERFORMED IN ITALY, 2021 122
TABLE 100 ITALY: KEY MACROINDICATORS 122
TABLE 101 ITALY: HEMOSTATS MARKET, BY TYPE, 2018–2021 (USD MILLION) 122
TABLE 102 ITALY: HEMOSTATS MARKET, BY TYPE, 2022–2028 (USD MILLION) 123
9.3.6 SPAIN 123
9.3.6.1 Growing healthcare budget and rising efforts to boost local manufacturing of medical products to drive market growth 123
TABLE 103 SURGICAL PROCEDURES PERFORMED IN SPAIN, 2021 124
TABLE 104 SPAIN: KEY MACROINDICATORS 124
TABLE 105 SPAIN: HEMOSTATS MARKET, BY TYPE, 2018–2021 (USD MILLION) 124
TABLE 106 SPAIN: HEMOSTATS MARKET, BY TYPE, 2022–2028 (USD MILLION) 125
9.3.7 RUSSIA 125
9.3.7.1 Long-term healthcare investment initiatives by government to support market growth 125
TABLE 107 RUSSIA: HEMOSTATS MARKET, BY TYPE, 2018–2021 (USD MILLION) 126
TABLE 108 RUSSIA: HEMOSTATS MARKET, BY TYPE, 2022–2028 (USD MILLION) 126
9.3.8 SWITZERLAND 127
9.3.8.1 Increasing public health insurance coverage to drive number of surgical procedures 127
TABLE 109 SURGICAL PROCEDURES PERFORMED IN SWITZERLAND, 2021 127
TABLE 110 SWITZERLAND: HEMOSTATS MARKET, BY TYPE, 2018–2021 (USD MILLION) 127
TABLE 111 SWITZERLAND: HEMOSTATS MARKET, BY TYPE, 2022–2028 (USD MILLION) 128
9.3.9 BELGIUM 128
9.3.9.1 Increasing demand for value-based healthcare services to drive market growth 128
TABLE 112 SURGICAL PROCEDURES PERFORMED IN BELGIUM, 2021 128
TABLE 113 BELGIUM: HEMOSTATS MARKET, BY TYPE, 2018–2021 (USD MILLION) 129
TABLE 114 BELGIUM: HEMOSTATS MARKET, BY TYPE, 2022–2028 (USD MILLION) 129
9.3.10 REST OF EUROPE 129
TABLE 115 REST OF EUROPE: PERCENTAGE OF GDP ON HEALTHCARE EXPENDITURE, BY COUNTRY 130
TABLE 116 REST OF EUROPE: HEMOSTATS MARKET, BY TYPE, 2018–2021 (USD MILLION) 130
TABLE 117 REST OF EUROPE: HEMOSTATS MARKET, BY TYPE, 2022–2028 (USD MILLION) 130
9.4 ASIA PACIFIC 131
FIGURE 27 ASIA PACIFIC: HEMOSTATS MARKET SNAPSHOT 132
TABLE 118 ASIA PACIFIC: HEMOSTATS MARKET, BY COUNTRY, 2018–2021 (USD MILLION) 133
TABLE 119 ASIA PACIFIC: HEMOSTATS MARKET, BY COUNTRY, 2022–2028 (USD MILLION) 133
TABLE 120 ASIA PACIFIC: HEMOSTATS MARKET, BY TYPE, 2018–2021 (USD MILLION) 134
TABLE 121 ASIA PACIFIC: HEMOSTATS MARKET, BY TYPE, 2022–2028 (USD MILLION) 134
TABLE 122 ASIA PACIFIC: HEMOSTATS MARKET, BY FORMULATION, 2018–2021 (USD MILLION) 134
TABLE 123 ASIA PACIFIC: HEMOSTATS MARKET, BY FORMULATION, 2022–2028 (USD MILLION) 135
TABLE 124 ASIA PACIFIC: HEMOSTATS MARKET, BY APPLICATION, 2018–2021 (USD MILLION) 135
TABLE 125 ASIA PACIFIC: HEMOSTATS MARKET, BY APPLICATION, 2022–2028 (USD MILLION) 135
9.4.1 ASIA PACIFIC: RECESSION IMPACT 136
9.4.2 CHINA 136
9.4.2.1 Growing number of hospitals and healthcare policy reforms to drive growth 136
TABLE 126 CHINA: HEMOSTATS MARKET, BY TYPE, 2018–2021 (USD MILLION) 137
TABLE 127 CHINA: HEMOSTATS MARKET, BY TYPE, 2022–2028 (USD MILLION) 137
9.4.3 JAPAN 138
9.4.3.1 Strong healthcare system and rising geriatric population to support market growth 138
TABLE 128 JAPAN: HEMOSTATS MARKET, BY TYPE, 2018–2021 (USD MILLION) 138
TABLE 129 JAPAN: HEMOSTATS MARKET, BY TYPE, 2022–2028 (USD MILLION) 139
9.4.4 INDIA 139
9.4.4.1 Rising healthcare awareness and favorable government support to propel market growth 139
TABLE 130 INDIA: HEMOSTATS MARKET, BY TYPE, 2018–2021 (USD MILLION) 140
TABLE 131 INDIA: HEMOSTATS MARKET, BY TYPE, 2022–2028 (USD MILLION) 140
9.4.5 AUSTRALIA 141
9.4.5.1 Rising prevalence of chronic diseases to drive market growth 141
TABLE 132 AUSTRALIA: HEMOSTATS MARKET, BY TYPE, 2018–2021 (USD MILLION) 141
TABLE 133 AUSTRALIA: HEMOSTATS MARKET, BY TYPE, 2022–2028 (USD MILLION) 142
9.4.6 SOUTH KOREA 142
9.4.6.1 Growing number of cosmetic surgeries to drive demand for hemostats 142
TABLE 134 SURGICAL PROCEDURES IN SOUTH KOREA, 2021 142
TABLE 135 SOUTH KOREA: HEMOSTATS MARKET, BY TYPE, 2018–2021 (USD MILLION) 143
TABLE 136 SOUTH KOREA: HEMOSTATS MARKET, BY TYPE, 2022–2028 (USD MILLION) 143
9.4.7 SINGAPORE 143
9.4.7.1 Government initiatives to promote healthcare services to support market growth 143
TABLE 137 SINGAPORE: HEMOSTATS MARKET, BY TYPE, 2018–2021 (USD MILLION) 144
TABLE 138 SINGAPORE: HEMOSTATS MARKET, BY TYPE, 2022–2028 (USD MILLION) 144
9.4.8 NEW ZEALAND 145
9.4.8.1 Increasing number of hip fractures to propel market growth 145
TABLE 139 NEW ZEALAND: HEMOSTATS MARKET, BY TYPE, 2018–2021 (USD MILLION) 145
TABLE 140 NEW ZEALAND: HEMOSTATS MARKET, BY TYPE, 2022–2028 (USD MILLION) 146
9.4.9 INDONESIA 146
9.4.9.1 Lucrative growth opportunities for players to boost market 146
TABLE 141 INDONESIA: HEMOSTATS MARKET, BY TYPE, 2018–2021 (USD MILLION) 147
TABLE 142 INDONESIA: HEMOSTATS MARKET, BY TYPE, 2022–2028 (USD MILLION) 147
9.4.10 MALAYSIA 147
9.4.10.1 Low healthcare costs, modern medical technology, and highly qualified doctors to favor market growth 147
TABLE 143 MALAYSIA: HEMOSTATS MARKET, BY TYPE, 2018–2021 (USD MILLION) 148
TABLE 144 MALAYSIA: HEMOSTATS MARKET, BY TYPE, 2022–2028 (USD MILLION) 148
9.4.11 REST OF ASIA PACIFIC 149
TABLE 145 REST OF ASIA PACIFIC: HEMOSTATS MARKET, BY TYPE, 2018–2021 (USD MILLION) 149
TABLE 146 REST OF ASIA PACIFIC: HEMOSTATS MARKET, BY TYPE, 2022–2028 (USD MILLION) 150
9.5 LATIN AMERICA 150
TABLE 147 LATIN AMERICA: HEMOSTATS MARKET, BY COUNTRY, 2018–2021 (USD MILLION) 151
TABLE 148 LATIN AMERICA: HEMOSTATS MARKET, BY COUNTRY, 2022–2028 (USD MILLION) 151
TABLE 149 LATIN AMERICA: HEMOSTATS MARKET, BY TYPE, 2018–2021 (USD MILLION) 151
TABLE 150 LATIN AMERICA: HEMOSTATS MARKET, BY TYPE, 2022–2028 (USD MILLION) 152
TABLE 151 LATIN AMERICA: HEMOSTATS MARKET, BY FORMULATION, 2018–2021 (USD MILLION) 152
TABLE 152 LATIN AMERICA: HEMOSTATS MARKET, BY FORMULATION, 2022–2028 (USD MILLION) 152
TABLE 153 LATIN AMERICA: HEMOSTATS MARKET, BY APPLICATION, 2018–2021 (USD MILLION) 153
TABLE 154 LATIN AMERICA: HEMOSTATS MARKET, BY APPLICATION, 2022–2028 (USD MILLION) 153
9.5.1 LATIN AMERICA: RECESSION IMPACT 153
9.5.2 BRAZIL 154
9.5.2.1 Brazil to dominate Latin American market for hemostats 154
TABLE 155 BRAZIL: HEMOSTATS MARKET, BY TYPE, 2018–2021 (USD MILLION) 154
TABLE 156 BRAZIL: HEMOSTATS MARKET, BY TYPE, 2022–2028 (USD MILLION) 154
9.5.3 MEXICO 155
9.5.3.1 Low-cost surgeries to drive medical tourism in Mexico 155
TABLE 157 MEXICO: HEMOSTATS MARKET, BY TYPE, 2018–2021 (USD MILLION) 155
TABLE 158 MEXICO: HEMOSTATS MARKET, BY TYPE, 2022–2028 (USD MILLION) 156
9.5.4 REST OF LATIN AMERICA 156
TABLE 159 REST OF LATIN AMERICA: HEMOSTATS MARKET, BY TYPE, 2018–2021 (USD MILLION) 156
TABLE 160 REST OF LATIN AMERICA: HEMOSTATS MARKET, BY TYPE, 2022–2028 (USD MILLION) 157
9.6 MIDDLE EAST & AFRICA 157
9.6.1 STRENGTHENING OF HEALTHCARE INFRASTRUCTURE TO SUPPORT MARKET GROWTH 157
TABLE 161 MIDDLE EAST & AFRICA: HEMOSTATS MARKET, BY TYPE, 2018–2021 (USD MILLION) 158
TABLE 162 MIDDLE EAST & AFRICA: HEMOSTATS MARKET, BY TYPE, 2022–2028 (USD MILLION) 158
TABLE 163 MIDDLE EAST & AFRICA: HEMOSTATS MARKET, BY FORMULATION, 2018–2021 (USD MILLION) 159
TABLE 164 MIDDLE EAST & AFRICA: HEMOSTATS MARKET, BY FORMULATION, 2022–2028 (USD MILLION) 159
TABLE 165 MIDDLE EAST & AFRICA: HEMOSTATS MARKET, BY APPLICATION, 2018–2021 (USD MILLION) 159
TABLE 166 MIDDLE EAST & AFRICA: HEMOSTATS MARKET, BY APPLICATION, 2022–2028 (USD MILLION) 160
9.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT 160
10 COMPETITIVE LANDSCAPE 161
10.1 OVERVIEW 161
10.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 161
10.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN HEMOSTATS MARKET 161
TABLE 167 OVERVIEW OF STRATEGIES DEPLOYED BY KEY HEMOSTAT MANUFACTURING COMPANIES 161
10.3 REVENUE ANALYSIS 163
FIGURE 28 REVENUE ANALYSIS OF TOP PLAYERS IN HEMOSTATS MARKET (2018–2022) 163
10.4 MARKET SHARE ANALYSIS 164
FIGURE 29 MARKET SHARE ANALYSIS OF TOP PLAYERS IN HEMOSTATS MARKET (2022) 164
TABLE 168 HEMOSTATS MARKET: DEGREE OF COMPETITION 164
10.5 COMPANY EVALUATION MATRIX 166
10.5.1 LIST OF EVALUATED VENDORS 166
10.5.2 STARS 166
10.5.3 EMERGING LEADERS 166
10.5.4 PERVASIVE PLAYERS 166
10.5.5 PARTICIPANTS 166
FIGURE 30 HEMOSTATS MARKET: COMPANY EVALUATION MATRIX (2022) 167
10.5.6 COMPANY FOOTPRINT 168
10.5.6.1 Product & regional footprint analysis 168
FIGURE 31 PRODUCT AND REGIONAL FOOTPRINT ANALYSIS OF TOP PLAYERS IN HEMOSTATS MARKET 168
TABLE 169 HEMOSTATS MARKET: COMPETITIVE BENCHMARKING OF KEY PLAYERS 168
TABLE 170 COMPANY FOOTPRINT, BY TYPE 169
TABLE 171 COMPANY FOOTPRINT, BY REGION 169
10.6 START-UP/SME EVALUATION MATRIX 170
10.6.1 PROGRESSIVE COMPANIES 170
10.6.2 RESPONSIVE COMPANIES 170
10.6.3 DYNAMIC COMPANIES 170
10.6.4 STARTING BLOCKS 170
FIGURE 32 HEMOSTATS MARKET: START-UP/SME EVALUATION MATRIX (2022) 171
10.7 COMPETITIVE SCENARIO 172
10.7.1 PRODUCT LAUNCHES & APPROVALS 172
TABLE 172 KEY PRODUCT LAUNCHES & APPROVALS (JANUARY 2018–OCTOBER 2023) 172
10.7.2 DEALS 172
TABLE 173 KEY DEALS (JANUARY 2018–OCTOBER 2023) 172
10.7.3 OTHER KEY DEVELOPMENTS 173
TABLE 174 OTHER KEY DEVELOPMENTS (JANUARY 2018–OCTOBER 2023) 173
11 COMPANY PROFILES 174
(Business overview, Products offered, Recent developments & MnM View)*
11.1 KEY PLAYERS 174
11.1.1 JOHNSON & JOHNSON 174
TABLE 175 JOHNSON & JOHNSON: BUSINESS OVERVIEW 174
FIGURE 33 JOHNSON & JOHNSON: COMPANY SNAPSHOT (2022) 175
11.1.2 BAXTER INTERNATIONAL 177
TABLE 176 BAXTER INTERNATIONAL: BUSINESS OVERVIEW 177
FIGURE 34 BAXTER INTERNATIONAL: COMPANY SNAPSHOT (2022) 178
11.1.3 PFIZER INC. 181
TABLE 177 PFIZER INC.: BUSINESS OVERVIEW 181
FIGURE 35 PFIZER INC.: COMPANY SNAPSHOT (2022) 182
11.1.4 B. BRAUN SE 184
TABLE 178 B. BRAUN SE: BUSINESS OVERVIEW 184
FIGURE 36 B. BRAUN SE: COMPANY SNAPSHOT (2022) 185
11.1.5 BECTON, DICKINSON AND COMPANY 187
TABLE 179 BECTON, DICKINSON AND COMPANY: BUSINESS OVERVIEW 187
FIGURE 37 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2022) 188
11.1.6 TELEFLEX INCORPORATED 190
TABLE 180 TELEFLEX INCORPORATED: BUSINESS OVERVIEW 190
FIGURE 38 TELEFLEX INCORPORATED: COMPANY SNAPSHOT (2022) 191
11.1.7 MEDTRONIC PLC 194
TABLE 181 MEDTRONIC PLC: BUSINESS OVERVIEW 194
FIGURE 39 MEDTRONIC PLC: COMPANY SNAPSHOT (2022) 195
11.1.8 HEMOSTASIS, LLC 196
TABLE 182 HEMOSTASIS, LLC: BUSINESS OVERVIEW 196
11.1.9 STRYKER CORPORATION 198
TABLE 183 STRYKER CORPORATION: BUSINESS OVERVIEW 198
FIGURE 40 STRYKER CORPORATION: COMPANY SNAPSHOT (2022) 199
11.1.10 INTEGRA LIFESCIENCES 201
TABLE 184 INTEGRA LIFESCIENCES: BUSINESS OVERVIEW 201
FIGURE 41 INTEGRA LIFESCIENCES: COMPANY SNAPSHOT (2022) 202
11.1.11 ADVANCED MEDICAL SOLUTIONS GROUP PLC 203
TABLE 185 ADVANCED MEDICAL SOLUTIONS GROUP PLC: BUSINESS OVERVIEW 203
FIGURE 42 ADVANCED MEDICAL SOLUTIONS GROUP PLC: COMPANY SNAPSHOT (2022) 204
11.1.12 SAMYANG HOLDINGS CORPORATION 206
TABLE 186 SAMYANG CORPORATION: BUSINESS OVERVIEW 206
FIGURE 43 SAMYANG CORPORATION: COMPANY SNAPSHOT (2022) 206
*Details on Business overview, Products offered, Recent developments & MnM View might not be captured in case of unlisted companies.

11.2 OTHER PLAYERS 208
11.2.1 MARINE POLYMER TECHNOLOGIES, INC. 208
11.2.2 GELITA MEDICAL GMBH 208
11.2.3 DILON TECHNOLOGIES, INC. 209
11.2.4 BETATECH MEDICAL 209
11.2.5 MERIL LIFE SCIENCES PVT. LTD. 210
11.2.6 BIOCER ENTWICKLUNGS-GMBH 210
11.2.7 UNILENE 211
11.2.8 KATSAN MEDICAL DEVICES 211
11.2.9 TRICOL BIOMEDICAL 212
11.2.10 3-D MATRIX MEDICAL TECHNOLOGY 212
11.2.11 HEMOSTAT MEDICAL GMBH 213
11.2.12 MEDTRADE PRODUCTS LIMITED 213
11.2.13 ALTAYLAR MEDICAL 214
12 APPENDIX 215
12.1 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 219
12.2 CUSTOMIZATION OPTIONS 221
12.3 RELATED REPORTS 221
12.4 AUTHOR DETAILS 222

❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 世界の止血剤市場（～2028年）：種類別（トロンビン、酸化再生セルロース、コンビネーション、ゼラチン、コラーゲン）、剤型別（マトリックス＆ゲル、シート＆パッド、スポンジ、パウダー）、用途別（整形外科、神経外科、心臓血管外科）、地域別(Hemostats Market by Type (Thrombin, Oxidized Regenerated Cellulose, Combination, Gelatin, Collagen), Formulation (Matrix & Gel, Sheet & Pad, Sponge, Powder), Application (Orthopedic, Neurological, Cardiovascular Surgery), Region - Global Forecast to 2028)]についてメールでお問い合わせはこちらでお願いします。

GlobalResearch.jp

グローバル市場調査/マーケットリサーチ会社：レポート販売と委託調査サービス提供 www.GlobalResearch.jp